Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


BNF update

Changes to BNF maximum dose for haloperidol

The British National Formulary (BNF) has reduced its maximum daily intramuscular (IM) dose for haloperidol from 20mg to 12mg. The maximum daily dose for the oral route remains at 20mg. 


This is the second time this year that the BNF has adjusted the dose for this antipsychotic: in May 2014 the maximum daily oral and IM doses were amended from 30mg to 20mg and from 18mg to 20mg, respectively, to reflect changes in the Haldol product literature. The latest change is in response to clinical feedback from mental health practitioners that the accepted bioavailability from the oral route is about 60% of that from the IM route.

The BNF doses differ from the product literature provided by some manufacturers, but the Medicines and Healthcare products Regulatory Agency is working on harmonising the literature for all haloperidol products, including generics.


Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20065648

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.